Clinical Significance of Persistent Hematuria Degrees in Primary IgA Nephropathy: A Propensity Score-Matched Analysis of a 10-Year Follow-Up Cohort
Overview
Authors
Affiliations
Introduction: The clinical significance of persistent hematuria degrees has not been expounded in primary IgA nephropathy (IgAN) and requires further research.
Methods: From January 2003 to May 2022, a total of 684 IgAN patients with persistent hematuria were enrolled to conduct a retrospective single-center study. Patients whose hematuria degree at baseline was higher than the second tertiles of the whole were included in the high-degree hematuria cohort (Hh), and the low-degree hematuria cohort (Lh) was constructed with 1:1 matched cases from the rest according to age, gender, and estimated glomerular filtration rate (eGFR) at baseline and follow-up time. Survival was determined using the Kaplan-Meier method (K-M) and generalized linear mixed-effects model (GLMM). Risk factors for survival were determined according to the Cox proportional hazards model.
Results: Both the Hh and Lh consisted of 228 cases. While the demographic data and the renal function at baseline were matched, both the K-M (p = 0.02) and GLMM (p = 0.04) proved that the prognosis of the Hh was significantly worse than that of the Lh within 10 years of follow-up. The higher persistent hematuria degree was an independent risk factor (3.93; 95% confidence interval, 1.33-11.6) associated with reaching the endpoint (eGFR decreased from the baseline ≥30% continuously or reached end-stage renal disease [ESRD]). The Hh had a significantly higher proportion of crescent (p = 0.003). The prognosis of the Hh was significantly worse than that of the Lh when accompanied by the crescent and presented an indistinct difference if the crescent was absent.
Conclusions: The clinicopathologic manifestation of IgAN patients with persistent high-degree hematuria was severer, and the prognosis was worse than those with persistent low-degree hematuria.
Contemporary review of IgA nephropathy.
Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.
PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.
Zand L, Fervenza F, Coppo R Clin Kidney J. 2023; 16(Suppl 2):ii19-ii27.
PMID: 38053974 PMC: 10695511. DOI: 10.1093/ckj/sfad232.
Lee M, Suzuki H, Nihei Y, Matsuzaki K, Suzuki Y Clin Kidney J. 2023; 16(Suppl 2):ii1-ii8.
PMID: 38053973 PMC: 10695519. DOI: 10.1093/ckj/sfad199.